Physician profile
Ted Triana
NPI 1902892482
$20,018.58
in general payments reported to CMS, 2019-2025
72 companies · $3,550 in 2025
The $3,550 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,749 · 2020: $1,855 · 2021: $3,238 · 2022: $3,191 · 2023: $2,989 · 2024: $3,447 · 2025: $3,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,980 · Education: $5.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,979.96 |
| Education | $5.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,845.36 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $2,397.54 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,722.66 | 2020-2025 | Vraylar, Ubrelvy, Viberzi |
| Bayer Healthcare Pharmaceuticals INC. | $1,108.12 | 2022-2025 | |
| Novo Nordisk INC | $968.22 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $713.50 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $691.33 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $602.54 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $563.49 | 2019-2025 | Spravato, Invega |
| Lilly USA, LLC | $541.69 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amarin Pharma, INC. | $533.96 | 2019-2022 | |
| Amgen INC. | $466.45 | 2019-2025 | Evenity, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $435.96 | 2021-2025 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $393.73 | 2019-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $364.39 | 2019-2024 | Gardasil 9, Vaxneuvance, Capvaxive |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Triana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.